The filing is a reverse-merger-style change of control with no financial data.
Price Chart
Executive Summary
SUIC Worldwide Holdings Ltd. completed a share-exchange acquisition of 51% of Vision Renu Corporation, issuing 30 million shares (approximately 35% of its fully diluted outstanding) to the target's shareholders. The transaction triggered a change in control: the entire prior board and officers resigned, and Chen King Te took over as Chairman, CEO, and director, with Shan Hua Peng as CFO and director. The filing includes a business description of Vision Renu's presbyopia laser and TMS depression devices but no financial statements for the target, leaving the financial impact and fair value of the deal unquantifiable.
Key Financial Metrics
Key Facts
- SUIC acquired 51% of Vision Renu Corporation in exchange for 30,000,000 shares of SUIC common stock.
- The Exchange Shares represent approximately 35% of SUIC's total outstanding shares on a fully-diluted basis.
- Prior directors and officers (Harriette Lo, Han Wei Wang, Yee Wei Tan) resigned; Chen King Te became Chairman, CEO, and director; Shan Hua Peng became CFO and director.
- Vision Renu focuses on medical devices: a scleral micro-ablation laser system for presbyopia (FDA certification ongoing) and a TMS device for depression (approved in Taiwan).
- The filing contains forward-looking statements about order volumes (150 units in 2026, 500 in 2027, 5,000 in 2028) but no audited financials are provided in the accessible text.
Financial Impact
No dollar amounts disclosed. Consideration was 30 million shares of SUIC common stock, representing ~35% of diluted shares. Deal value cannot be determined without a market price or financial statements.
Risk Factors
- Massive dilution: 30 million new shares represent 35% of fully diluted equity.
- No historical financials for Vision Renu provided in the text; profitability and cash flow are unknown.
- Revenue and order forecasts are unverified forward-looking statements with no contractual guarantees.
- Regulatory risk: FDA approval for the presbyopia laser is pending; TMS device approval is only in Taiwan.
- Integration risk: the combined entity has only 7 employees and lacks a track record in the U.S. market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001477932-26-004250 |
| Document: suic_8k.htm | 0001477932-26-004250 |
| Document: 0001477932-26-004250-index-headers.html | 0001477932-26-004250 |
| Document: 0001477932-26-004250-index.html | 0001477932-26-004250 |
| Document: 0001477932-26-004250.txt | 0001477932-26-004250 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers